NVAX - Novavax EV/EBITDA Multiple

Corporate company logo of Novavax (NVAX)

Risks of declining demand for COVID-19 products are neutralized by partnerships, while the focus has shifted to the influenza vaccine. The EV/EBITDA business valuation level on GURU.Markets reflects the company's value dynamics, where the value 0.00 represents the current figure. Novavax, Inc. (NVAX) maintains stability through its Matrix-M biodefense platform and optimized international logistics, which minimize regulatory barriers during deliveries.

NVAX Novavax Pharma: Business Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/12/2026

Analytical breakdowns for Novavax, Inc.

- stock price and consensus target price:
Stock Quotes Novavax Corp|NVAX - Price Target Chart
- market capitalization statistics:
Market Capitalization Novavax Pharma|NVAX - Company Buyout Price
- issuer book value statistics:
Net Assets per Single Share Novavax|NVAX - Accounting Value of Company|Market Cap to Net Assets Ratio novavax.com|NVAX - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Novavax, Inc.|NVAX - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Novavax|NVAX - Company Aggregate Debt|Debt to Book Capitalization Ratio Novavax Pharma|NVAX - Long-Term Debt|Company Current Liabilities Novavax|Quick Ratio novavax.com
- business earnings and investment ratios data:
NVAX - Net Profit|Future Profit Novavax, Inc.|NVAX - Price to Earnings Ratio|Forward P/E Multiple Novavax, Inc.|NVAX - PEG Multiple|Enterprise Value to EBITDA Ratio Novavax Pharma|NVAX - Operating profit before amortization|Net earnings per share for the last 12 months Novavax|NVAX - Earnings per share for the trailing year|Quarterly EPS earnings growth novavax.com|NVAX - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Novavax, Inc.
Fundamental company valuation:NVAX (Novavax Corp)
Original product of Novavax

Novavax, Inc. (NVAX) specializes in developing protein-based vaccines for public healthcare systems, which requires significant capital expenditures. The multiple compares the total enterprise value to earnings before interest, taxes, depreciation, and amortization, allowing for an assessment of debt management efficiency; meanwhile, the company's trend EV/EBITDA level helps investors determine the risk of overpayment or the likelihood of an asset value correction.

Competitor analysis

Gilead Sciences Inc - Enterprise Value to EBITDA Ratio|Cidara - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CureVac N.V. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio valneva.com VALN|Vir Biotechnology (VIR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SIGA Technologies Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio EBS|EV/EBITDA Multiple Atea Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Invivyd, Inc. (IVVD)|Total Company Value to Operating Income Before Depreciation Ratio enanta.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inovio INO|HLVX: Enterprise Value to Operating Income Before Depreciation|KLRS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Dyadic International|NNVC (nanoviricides.com) - Enterprise Value to EBITDA Ratio|TLPH (talphera.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|COCP (Cocrystal Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Traws Therapeutics|Enterprise Value to EBITDA Ratio DWTX (Dogwood Therapeutics, Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization QLGN (Qualigen Corp)|EV/EBITDA Multiple ALVR (AlloVir)|EV/EBITDA Multiple VBI Vaccines, Inc. VBIV|VIRI: Enterprise Value to EBITDA Ratio|VXRT (Vaxart, Inc.) - Enterprise Value to Operating Income Before Depreciation